The panel referred "potential thromboembolic events" as the potentially fatal formation of a blood clot that could break loose and be carried by the blood stream to block another vessel.
The National Committee on Adverse Events Following Immunization (AEFI) told the Union Ministry of Health and Family Welfare that very few cases of blood clotting associated with COVID-19 vaccination have been reported in India. The report was submitted by the committee on May 17.
The panel said that the cases of bleeding and clotting after getting inoculated by the Covid jab in India are "miniscule" and "in line with the expected number of diagnoses of these conditions." According to the panel, more than 23,000 cases of adverse effects have been reported through the CO-WIN App so far. Of these, 700 cases were found with serious and severe effects. The panel conducted an in-depth review of 498 of these serious and severe cases, of which 26 cases were reported of "potential thromboembolic events" (blood clotting) after they were administered the Covishield vaccine.
The panel referred "potential thromboembolic" as the potentially fatal formation of a blood clot that could break loose and be carried by the blood stream to block another vessel. The panel said that Covaxin (developed by Bharat Biotech) reported no potential thromboembolic event after the vaccine was administered.
However, the ministry has advised people to be aware of the serious and severe effects including signs of thromboembolic events after getting inoculated. Symptoms that people have been advised to look out for are breathlessness, pain in the chest or limbs, pinhead-sized red spots or bruising of skin in areas other than the injection site and persistent abdominal pain.
The Brief. Sign up to receive the top stories you need to know right now.